Cardiology
|
Large Coronary Artery Disease |
REVERSE
Randomised Trial of Drug-CoatEd Balloon Versus Drug-Eluting Stent foR Clinical OutcomeS in Patients with LargE Coronary Artery Disease :AAG-G-H-2124
Link to ClinicalTrial.gov
|
Dr Ho Hee Hwa
|
Endocrinology
|
Type 2 Diabetes Mellitus
|
ADOPT (Asian Diabetes Outcomes Prevention Trial)
A multinational, randomized open-label, parallel-group, active-controlled, two-arm, long-term morbidity and mortality trial involving intensive preventive therapy (high dose renin-angiotensin-aldosterone system inhibitors [RAASi], beta-blockade, sodium-glucose co-transporter 2 inhibitors [SGLT2i]) among biomarker (N-terminal pro-B-type natriuretic peptide, NT-proBNP)-identified high-risk type 2 DM patients without pre-existing cardiovascular disease
Link to ClinicalTrial.gov
|
Dr Rinkoo Dalan
|
Gastroenterology & Hepatology
|
NVUGIB
|
NBM-NP004
A Prospective, Multi-center, Single-arm, Pilot Clinical Trial to Evaluate Efficacy and Safety of Nexpowder™ for Hemostatic Treatment of Non-variceal, Upper Gastrointestinal Bleeding
Link to ClinicalTrial.gov |
Dr Chew Wei Da
|
Interventional Radiology
|
Critical Limb Ischemia
|
FUTURE-BTK
Randomized Controlled Trial of First Sirolimus Coated Balloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
Link to ClinicalTrial.gov
|
Dr Pua Uei
|
Interventional Radiology
|
Critical Limb Ischemia
|
FUTURE-SFA
Randomized Controlled Trial of First SirolimUs CoaTed Balloon VersUs StandaRd Balloon Angioplasty in The TrEatment of Superficial Femoral Artery and Popliteal Artery Disease.
Link to ClinicalTrial.gov
|
Dr Pua Uei
|
Ophthalmology
|
TED
|
GP44467 SatraGo1
A Phase III, Randomized, Double-masked, Placebo-controlled, Multicenter Study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate to Severe Thyroid Eye Disease
Link to ClinicalTrial.gov
|
Dr Lee Kuan Ming Llewellyn
|
Ophthalmology
|
Uveitic Macular Edema
|
SANDCAT
A Phase III, Multicenter, Randomized, Double-masked, Sham-controlled study to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in patients with Uveitic Macular Edema
Link to ClinicalTrial.gov
|
Dr Rupesh Agrawal
|
Ophthalmology
|
mCNV
|
POYANG
A Phase III, Multicenter, Randomized, Double-masked, Active Comparator-controlled study to evaluate the efficacy and safety of Faricimab in patients with Choroidal Neovascularization secondary to Pathologic Myopia
Link to ClinicalTrial.gov
|
Dr Karen Chia
|
RAI
|
SLE
|
SIRIUS-SLE 1
A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of two regimens of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus
Link to ClinicalTrial.gov
|
Dr Howe Hwee Siew |
RAI
|
Gout
|
JW21301
A multi-center, randomized, double-blind, active-controlled, therapeutic confirmatory, phase III study to compare and evaluate the efficacy and safety of Epaminurad with Febuxostat in gout patients
Link to ClinicalTrial.gov
|
Dr Koh Li Wearn
|
RAI
|
HAE
|
RAPIDe-3
Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema
Link to ClinicalTrial.gov
|
Dr Tan Sze-Chin
|
Renal
|
CKD
|
ALPINE 1 22040
A Phase 2b dose-finding, randomized, placebo-controlled, double-blind study to evaluate efficacy and safety of BAY 3283142 on top of standard of care in reducing albuminuria in patients with chronic kidney disease
Link to ClinicalTrial.gov
|
Dr Yeo See Cheng
|
Renal
|
IgAN |
IMAGINATION WA43966
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of RO7434656, An Antisense Inhibitor Of Complement Factor B, In Patients With Primary Iga Nephropathy At High Risk Of Progression [WA43966]
Link to ClinicalTrial.gov
|
Dr Yeo See Cheng
|
Renal
|
IgAN
|
VT1201 ORIGIN 3
A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)
Link to ClinicalTrial.gov
|
Dr Yeo See Cheng
|
Renal
|
LN
|
CVAY736K12301 SIRIUS-LN
A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in participants with active lupus nephritis
Link to ClinicalTrial.gov
|
Dr Yeo See Cheng
|
Renal
|
ACKD
|
TRACK
Treatment of cardiovascular disease with low dose Rivaroxaban in Advanced Chronic Kidney disease
Link to ClinicalTrial.gov
|
Dr Weng Wanting
|
Renal
|
LN
|
CLNP023K12201 - LN Trial
An adaptive, randomized, double-blind, dose exploration, parallel group, placebo-controlled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with standard-of-care with and without oral corticosteroids in adult patients with active lupus nephritis Class III-IV, +/- V (Protocol Number - CLNP023K12201)
Link to ClinicalTrial.gov
|
Dr Yeo See Cheng
|
Respiratory
|
Pulmonary Fibrosis
|
1462-0004
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF)
Link to ClinicalTrial.gov
|
Dr Chai Gin Tsen
|
Respiratory
|
Pulmonary Fibrosis
|
1490-0004
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally twice daily over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically significant cough
Link to ClinicalTrial.gov
|
Dr Chai Gin Tsen
|
| |
| |